沙美特罗丙酸氟替卡松联合孟鲁司特钠治疗咳嗽变异型哮喘的疗效观察

目的 观察沙美特罗丙酸氟替卡松联合孟鲁司特钠治疗成人咳嗽变异型哮喘的疗效.方法 采用完全随机对照试验方法将93例咳嗽变异型哮喘患者分为3组各31例,观察组吸入沙美特罗/丙酸氟替卡松(50 μg/250 μg)1吸,早晚各1次,孟鲁司特钠10 mg/次,顿服,共8周.沙美特罗/丙酸氟替卡松组吸入沙美特罗/丙酸氟替卡松(50 μg/250μg)1吸,早晚各1次,共8周.孟鲁司特钠组服用孟鲁司特钠10 mg/次,顿服,共8周.比较3组患者症状改善和肺功能变化情况.结果 治疗后症状积分均较治疗前低,差异有统计学意义(P＜0.05),3组组间差异有统计学意义(P＜0.05).8周治疗后观察组、沙美特罗/丙酸氟替卡松组和孟鲁司特钠组第1秒用力呼气容积(FEV1)、FEV1占预计值的百分比(FEV1％)、呼气峰流速(PEF)与治疗前比较差异均有统计学意义(均P＜0.05)；治疗后观察组FEV1、FEV1％、PEF高于沙美特罗/丙酸氟替卡松组及孟鲁司特钠组,差异均有统计学意义 FEV1:(1.65±0.52)L比(1.52±0.63)L,(1.46±0.53)L;FEV1％:(64.41±10.31)％比(62.81±11.03)％,(59.02±11.19)％; PEF:(5.24±1.15) L/min比(6.10±1.28) L/min,(6.62±1.00) L/min,均P＜0.05].结论 沙美特罗/丙酸氟替卡松与孟鲁司特钠联合应用治疗咳嗽变异型哮喘疗效优于单用沙美特罗/丙酸氟替卡松或孟鲁司特钠.

The efficacy of salmeterol/fluticasone propionate combined with montelukast soudium in treatment of coughvariant asthma

Objective To observe the efficacy of salmeterol/fluticasone propionate combined with montelukast soudium in treatment of adult patients with cough variant asthma. Methods Ninety-three patients were randomly divided into three groups. The observation group inhaled salmeterol/fluticasone propionate （50 μg/250 μg） and took montelukast soudium 10 mg one time for eight weeks. Two other control groups： one inhaled salmeterol/fluticasone propionate （ salmeterol/fluticasone propionate group） and the other took montelukast soudium （ montelukast soudium group）. The improvement of symptom and changes of pulmonary function in three groups were compared. Results After treatment the symptom scores were all lower （P 〈 0. 05）, the difference was statistically significant among the 3 groups （P 〈 0. 05）. After 8 weeks of treatment, forced expiratory volume in one second （ FEV1 ）, FEV1 percentages of predicted （ FEV1 % ）, peak expiratory flow （PEF） in the observation group, salmeterol/fluticasone propionate group and montelukast soudium group had significant differences （ all P 〈 0. 05 ） ; after treatment, FEV1, FEV1% and PEF in observation group were all higher than those in the salmeterol/ fluticasone propionate group and montelukast soudium group, the differences were statistically significant FEV： （1.65 ±0.52）Lvs （1.52 ±0.63）L, （1.46±0.53）L; FEV1%： （64.41± 10.31）% vs （62.81 ±11.03）%, （59.02 ±11.19）%; PEF： （5.24± 1.15） L/min vs （6.10 ±1.28）L/min, （6. 62 ±1. 00）L/min, allP〈 0. 051. Conclusion The salmeterol/fluticasone propionate combined with montelukast soudium is superior to the salmeterol / fluticasone propionate or montelukast soudium in treatment of cough variant asthma.